Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy
Status:
Terminated
Trial end date:
2018-05-16
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn about the tolerability of nivolumab in
patients who have bladder cancer, were previously treated with BCG immunotherapy, and who
have a cystectomy (removal of all or part of the bladder) scheduled as part of their standard
care.
This is an investigational study. Nivolumab is FDA approved and commercially available to
treat metastatic (has spread) melanoma or non-small cell lung cancer (NSCLC) after the
disease has gotten worse while receiving platinum-based chemotherapy. The use of nivolumab in
this study is considered investigational.
Up to 10 participants will take part in this study. All will be enrolled at MD Anderson.